Detection of aspirin resistance by PFA-100: Prevalence and aspirin compliance in patients with chronic stable angina

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 4, 2005, Pages 420-425

  Crowe, Basil ^b   Abbas, Syed ^b   Meany, Brendan ^b   De Haan, Jacob ^c   Cahill, Mary R ^a,b  

^a University College Cork   (Ireland)

^b UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^c Dade Behring   (Germany)

Author keywords

Aspirin resistance; Nitrates; PFA 100; Platelet activation; Platelets; Salicylate levels

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; PLATELET FUNCTION ANALYZER 100; SALICYLIC ACID;

ADULT; AGED; CHRONIC DISEASE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MALE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RELIABILITY; STABLE ANGINA PECTORIS; STROKE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; ASPIRIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRATES; PATIENT COMPLIANCE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREVALENCE; REFERENCE VALUES; SALICYLATES; TIME FACTORS;

EID: 25444443409     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-916677     Document Type: Conference Paper

References (37)

1. Kannel WB. Bishop Lecture: Contribution of the Framingham Study to preventive cardiology. J Am Coll Cardiol 1990;15:206-211
2. Heller RF, Chinn S, Pedoe HD, Rose G. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project. BMJ (Clin Res Ed) 1984;288:1409-1411
3. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multi-center trial. N Engl J Med 1985;313:1369-1375
4. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-403
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
6. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991;84:613-617
7. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987;316:1514-1518
8. Vilen L, Johansson S, Kutti J, Cronberg S, Vedin A, Wilhelmsson C. ADP-induced platelet aggregation in young female survivors of acute myocardial infarction and their female controls. Acta Med Scand 1985;217:9-13
9. [No authors listed]. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists Collaboration. Br Med J (Clin Res Ed) 1988;296:320-331
10. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995;11:221-227
11. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-2336
12. Cahill M, Mistry R, Chapman C, Barnett DB. Effects of age, sex, and oral contraceptives on the platelet membrane fibrinogen binding site (glycoprotein IIb/IIIa). Br J Clin Pharmacol 1992;33:11-15
13. Cahill MR, Macey MG, Newland AC. Fixation with formaldehyde induces expression of activation dependent platelet membrane glycoproteins, P-selectin (CD62) and GP53 (CD63). Br J Haematol 1993;84:527-529
14. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733-744
15. Kundu SK, Heilmann EJ, Sio R, et al. Characterization of an in vitro platelet function analyzer, PFA-100™. Semin Thromb Hemost 1995;21:106-112
16. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function function analyzer-PFA-100. Semin Thromb Hemost 1995;21(suppl 2):106-112
17. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16:1-20
18. Elwood PC, Renaud S, Sharp DS, Beswick AD, O'Brien JR, Yarnell JW. Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. Circulation 1991;83:38-44
19. Zahavi J, Kakkar VV. β-thromboglobulin-a specific marker of in vivo platelet release reaction. Thromb Haemost 1980;44:23-29
20. Marshall PW, Williams AJ, Dixon RM, et al. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 1997;44:151-155
21. Cattaneo M, Federici AB, Lecchi A, et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999;82:35-39
22. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998;91:1325-1331
23. Mammen EF, Comp PC, Gosselin R, et al. PFA-100™ system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202
24. Bock M, de Haan J, Beck K-H, et al. Standardization of the PFA-100 platelet function test in 105 mmol/L buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol 1999;106:898-904
25. Heilmann EJ, Kundu SK, Sio R, Garcia C, Gomez R, Christie DJ. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system. Thromb Res 1997;87:159-164
26. Cahill MR, Macey MG, Dawson JR, Newland AC. Prevention of restenosis after angioplasty. Lancet 1994;343:1361
27. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-989
28. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981;304:685-691
29. De Boer AC, Turpie AGG, Butt RW, Johnston RV, Genton E. Platelet release and thromboxane synthesis in symptomatic coronary artery disease. Circulation 1982;66:327-333
30. Gormsen J, Dalsgaard-Neilsen J, Agerskov-Andersen L. ADP-induced platelet aggregation in vitro in patients with ischaemic heart disease and peripheral thrombo-atherosclerosis. Acta Med Scand 1977;201:509-513
31. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235
32. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms and clinical significance. Thromb Haemost 2002;88:711-715
33. von Pape K, Aland E, Bohner J. Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood samples. Thromb Res 2000;98:295-299
34. Fitzgerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 2003;361:542-543
35. Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet PLA1 (GP IIIa) polymorphism but not with c807T (GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003;42:1115-1119
36. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-574
37. Marcus AJ, Broekman MJ, Pinsky DJ. COX inhibitors and thromboregulation. N Engl J Med 2002;347:1025-1026